Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cannabidiol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 5/20 | 1.00 |
| ▸ | CNR2 | P34972 | 9/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 6/20 | 1.00 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 1.00 |
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | PDE9A | O76083 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | LDHA | P00338 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cannabidiol SCHEMBL16224872 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL1644403 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL119679 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL122259 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL23934764 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL2229837 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL23460334 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL20201772 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL20930113 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 | |
| Cannabidiol SCHEMBL16212393 | 1.00 | CNR2 (1.00) | CNR2OPRM1CNR1TRPV1GPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021074403-A1 | CONTROLLED RELEASE FORMULATIONS OF HIGHLY LIPOPHILIC PHYSIOLOGICALLY ACTIVE SUBSTANCES | ADD ADVANCED DRUG DELIVERY TECHNOLOGIES LTD. (CH) | 2021-04-22 | — | — | WO | claimed |
| WO-2021074399-A1 | CONTROLLED RELEASE FORMULATIONS OF HIGHLY LIPOPHILIC PHYSIOLOGICALLY ACTIVE SUBSTANCES | ADD ADVANCED DRUG DELIVERY TECHNOLOGIES LTD. (CH) | 2021-04-22 | — | — | WO | claimed |
| EP-3808336-A1 | CONTROLLED RELEASE FORMULATIONS OF HIGHLY LIPOPHILIC PHYSIOLOGICALLY ACTIVE SUBSTANCES | ADD Advanced Drug Delivery Technologies, Ltd. (CH) | 2021-04-21 | — | — | EP | claimed |
| EP-3808341-A1 | CONTROLLED RELEASE FORMULATIONS OF HIGHLY LIPOPHILIC PHYSIOLOGICALLY ACTIVE SUBSTANCES | ADD Advanced Drug Delivery Technologies, Ltd. (CH) | 2021-04-21 | — | — | EP | claimed |
| US-8324408-B2 | Method for the preparation of dronabinol | BIONORICA AG | 2012-12-04 | — | — | US | claimed |
| US-11964955-B2 | Mixtures of cannabinoid compounds, and production and use thereof | SYMRISE AG (DE) | 2024-04-23 | — | — | US | disclosed |
| EP-3840852-B1 | PROCESS FOR THE PRODUCTION OF CANNABINOIDS | BESSOR PHARMA LLC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-11707444-B2 | Antiviral composition for SARS-CoV-2 containing cannabinoids as active ingredient | RESEARCH COOPERATION FOUNDATION OF YEUNGNAM UNIVERSITY (KR) | 2023-07-25 | — | — | US | disclosed |
| EP-3455213-B1 | METHOD FOR PURIFYING CANNABINOID COMPOUNDS VIA SIMULATED MOVING BED CHROMATOGRAPHY | SYMRISE AG (DE) | 2021-11-24 | — | — | EP | disclosed |
| WO-2021074399-A1 | CONTROLLED RELEASE FORMULATIONS OF HIGHLY LIPOPHILIC PHYSIOLOGICALLY ACTIVE SUBSTANCES | ADD ADVANCED DRUG DELIVERY TECHNOLOGIES LTD. (CH) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021074403-A1 | CONTROLLED RELEASE FORMULATIONS OF HIGHLY LIPOPHILIC PHYSIOLOGICALLY ACTIVE SUBSTANCES | ADD ADVANCED DRUG DELIVERY TECHNOLOGIES LTD. (CH) | 2021-04-22 | — | — | WO | disclosed |
| EP-3808341-A1 | CONTROLLED RELEASE FORMULATIONS OF HIGHLY LIPOPHILIC PHYSIOLOGICALLY ACTIVE SUBSTANCES | ADD Advanced Drug Delivery Technologies, Ltd. (CH) | 2021-04-21 | — | — | EP | disclosed |
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20100210860-A1 | METHOD FOR THE PREPARATION OF DRONABINOL | BIONORICA AG (DE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210860-A1 | METHOD FOR THE PREPARATION OF DRONABINOL | BIONORICA AG (DE) | 2010-08-19 | — | — | US | disclosed |
| EP-1896389-A1 | METHOD FOR THE PRODUCTION OF DRONABINOL FROM CANNABIDIOL, USING A MOLECULAR SIEVE | Bionorica AG (DE) | 2008-03-12 | — | — | EP | disclosed |
| EP-1896389-A1 | METHOD FOR THE PRODUCTION OF DRONABINOL FROM CANNABIDIOL, USING A MOLECULAR SIEVE | Bionorica AG (DE) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006136273-A1 | METHOD FOR THE PRODUCTION OF DRONABINOL FROM CANNABIDIOL, USING A MOLECULAR SIEVE | BIONORICA AG (DE) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006136273-A1 | METHOD FOR THE PRODUCTION OF DRONABINOL FROM CANNABIDIOL, USING A MOLECULAR SIEVE | BIONORICA AG (DE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964955-B2 | Mixtures of cannabinoid compounds, and production and use thereof | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885OPRM1 122/4885 |
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRPC4, TRPC1, TRPC3 | CNR1 344/4885CNR2 192/4885OPRM1 44/4885 |
| US-20100210860-A1 | METHOD FOR THE PREPARATION OF DRONABINOL | CNR1, CNR2, CCKBR | CNR1 1/4885CNR2 2/4885OPRM1 42/4885 |
| US-11707444-B2 | Antiviral composition for SARS-CoV-2 containing cannabinoids as active ingredient | TMPRSS2, ACE2, CNR2 | CNR1 4/4885CNR2 3/4885OPRM1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.